Patent Yard Sign in
Canadian application, no grantCanada

Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions

CA 2445763 A1 · Owner: Toleikis, Philip M. · Inventors: Toleikis, Philip M.; Liggins, Richard; Hunter, William

CIPO record

Overview

Drawings and full text

Its claims, description and drawings are in the Canadian Patents Database.

Open the CIPO record

Abstract From the Canadian patent

Disclosed herein are compositions and methods for treating a variety of inflammatory conditions (e.g. inflammatory arthritis adhesions, tumor , excision sites, and fibroproliferative diseases of the eye). For example there is provided a composition comprising a protein or polysaccharide containing dispersed (e.g. in micelle or liposome form) anti-microtubule agent, which may be formulated for administration to a patient in need thereof.

Read the whole patent

Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.

Why it's free to use

  • Filed May 1, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 1, 2022.
  • A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 1, 2024.
  • We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledMay 1, 2002
GrantedNo grant recorded
Term endedMay 1, 2022
Patent numberCA 2445763 A1
Classification (IPC)A61K31/33 +2 more

Timeline

Timeline From CIPO dates

2003200520072009201120132015201720192021Application filedMay 1, 2002Term endedMay 1, 2022

Sources & verification

Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.